drugset / Trial / NCT03571087

Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia

NCT03571087

Phase 3 Completed 374 enrolled Hanlim Pharm. Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of HL140 in patients with primary hypercholesterolemia.

Timeline

Start
2014-09
Primary completion
2015-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 5 mg
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 20 mg

Indications